BIOGEN INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BIOGEN INC. treasury stock, value, acquired, cost method for the quarter ending 2022-09-30 was $250.00M.
- BIOGEN INC. treasury stock, value, acquired, cost method for the quarter ending 2022-06-30 was $500.00M.
- BIOGEN INC. treasury stock, value, acquired, cost method for the quarter ending 2012-12-31 was $21.52M, a 80.68% decline year-over-year.
- BIOGEN INC. treasury stock, value, acquired, cost method for the quarter ending 2012-09-30 was $53.20M.
- BIOGEN INC. treasury stock, value, acquired, cost method for fiscal 2018 was $3.00B.
- BIOGEN INC. treasury stock, value, acquired, cost method for fiscal 2016 was $1.00B, a 80.00% decline from fiscal 2015.
- BIOGEN INC. treasury stock, value, acquired, cost method for fiscal 2015 was $5.00B, a 463.82% increase from fiscal 2014.
- BIOGEN INC. treasury stock, value, acquired, cost method for fiscal 2014 was $886.80M, a 121.53% increase from fiscal 2013.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2022-09-30 | $250.00M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $500.00M 10-Q · filed 2023-07-25 | |
| 2018-12-31 | $3.00B 10-K · filed 2020-02-06 | |
| 2016-12-31 | $1.00B 10-K · filed 2019-02-06 | |
| 2015-12-31 | $5.00B 10-K · filed 2018-02-01 | |
| 2014-12-31 | $886.80M 10-K · filed 2017-02-02 | |
| 2013-12-31 | $400.30M 10-K · filed 2016-02-03 | |
| 2012-12-31 | $21.52M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $984.72M 10-K · filed 2015-02-04 |
| 2012-09-30 | $53.20M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $446.80M 10-Q · filed 2012-07-24 | |
| 2011-12-31 | $111.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $497.98M 10-K · filed 2014-02-06 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | |
| 2011-06-30 | $191.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | |
| 2011-03-31 | $195.30M 10-Q · filed 2012-05-01 | |
| 2010-12-31 | $2.08B 10-K · filed 2013-02-05 | |
| 2010-03-31 | $557.60M 10-Q · filed 2011-04-21 | |
| 2009-12-31 | $751.17M 10-K · filed 2012-02-03 | |
| 2008-12-31 | -$738.94M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |